Pengaruh Komorbid dan Jenis Terapi terhadap Outcome Kolesterol Total Pasien Dislipidemia

https://doi.org/10.22146/jmpf.64328

Fitri Apriliany(1*), Zullies Ikawati(2), I Dewa Putu Pramantara(3)

(1) Study Program of Pharmacy, Faculty of Health Science, University of Bumigora Mataram
(2) Graduate Program of Clinical Pharmacy, Faculty of Pharmacy, Universitas Gadjah Mada
(3) KSM Penyakit Dalam, RSUP DR Sardjito Yogyakarta
(*) Corresponding Author

Abstract


Dislipidemia is one of the main risk factors of cardiovascular diseases that contributed more than 25% of death in this world. Hypertension and DM are associated with comorbidity in chronic disease, include of dislipidemia. This study aimed to determine the effect of comorbid and type of therapy on clinical outcomes in the outpatient installation at Puskesmas Jetis, Yogyakarta. This research is descriptive observational analytic with a cross-sectional. Data derived from primary data and secondary data. The inclusion criteria were patients dyslipidemia, received antidyslipidemia at least 3 months before the study, completed medical record, willing to able respondents, and can communicate well. Those who were pregnant or breastfeeding were excluded from the study. Data analysis used the Wilcoxon test. Most of respondents were majority dominated by women (86,14%), hypertension is the most comorbid (42,46%), most of patients used simvastatin (76,24%), gemfibrozil (16,83%), and combination of simvastatin+gemfibrozil (6,93%). The analysis showed that there was a significant effect on patients with comorbid diabetes and used simvastatin value before and after therapy for 3 months (p<0,05). This result showed that there was an effect of diabetes comorbidities and simvastatin therapy on the total cholesterol of patients, So this study implies that in providing statin therapy need to consider comorbid because they will affect to total cholesterol which one comorbid management that good need to achieve optimal therapeutic and type of therapy must be correct to improve outcome.

Keywords


Dyslipidemia; Gemfibrozil; Total cholesterol; comorbid; simvastatin

Full Text:

PDF


References

  1. PERKENI. Panduan Pengelolaan Dislipidemia Di Indonesia -2015. Juli 2015. PB. PERKENI; 2015.
  2. Grover A, Rehan HS, Gupta LK, Yadav M. Correlation of compliance to statin therapy with lipid profile and serum HMGCoA reductase levels in dyslipidemic patients. Indian Heart J. 2017;69(1):6-10. doi:10.1016/j.ihj.2016.07.007
  3. Tharaheswari M, Yogamoorthi A. Studies on Dyslipidemia in Diabetic and Non Diabetic Hypertensive Patients. Am J Phytomedicine Clin Ther. 2014;2(5):636-643.
  4. Arifin AY, Ernawati F, Prihatini M. Hubungan Kadar Glukosa Darah Terhadap Peningkatan Kadar Lemak Darah Pada Populasi Studi Kohor Kecamatan Bogor Tengah 2018 bahwa terjadi peningkatan prevalensi PTM hubungan kadar glukosa darah dikaitkan yang berasal dari darah vena , selanjutnya Laboratori. J Biotek Medisian Indones Vol; 822019 Hal 87-93. 2018;vol; 8.2.2:87-93.
  5. Gemilang B, Yanwirasti Y, Miro S. Hubungan Kadar Trigliserida dan Kolesterol-HDL Terhadap Kadar Alanine Aminotransferase pada Pasien Non Alcoholic Fatty Liver Disease. J Kesehat Andalas. 2016;5(1):179-184. doi:10.25077/jka.v5i1.465
  6. Rasyid NQ, Muawanah, Rahmawati. Gangguan dislipidemia pada pasien diabetes mellitus. Pros Semin Has Penelit. 2018;2018(2014):149-152.
  7. Betaubun, A.M; Nurahmi; Bahrun, U; Pakasi R. Indeks Aterogenik Plasma di Penyakit Diabetes Melitus Tipe 2. Indones J Clin Pathol Med Lab. 2015;22(1):82-86.
  8. Mithal A, Majhi D, Shunmugavelu M, Talwarkar PG, Vasnawala H, Raza AS. Prevalence of dyslipidemia in adult Indian diabetic patients: A cross sectional study (SOLID). Indian J Endocrinol Metab. 2014;18(5):642-647. doi:10.4103/2230-8210.139220
  9. Rahmawati ND, Dewi Sartika RA. Analisis Faktor-Faktor Risiko Kejadian Dislipidemia pada Karyawan Pria Head Office PT.X, Cakung, Jakarta Timur. Nutr Diaita. 2020;12(01):1-9. doi:10.47007/nut.v12i01.3014
  10. Pakpahan J, Sarumpaet S, Lubis R. Hubungan Dislipidemia dan Hipertensi Terhadap Kejadian Penyakit Jantung Koroner Pada Anggota Tentara Nasional Indonesian (Tni) < 40 Tahun Di Rumah Sakit Tk Ii Putri Hijau Medan. J Muara Sains, Teknol Kesehatan, dan Ilmu Kesehat. 2018;2(1):291-298.
  11. Tan NC, Koh EYL, Goh CC, Goh PSC, Koh KH. A cross-sectional study of gender differences in lifestyle behavior and usage of medications among community-dwelling Asians towards achieving their LDL-Cholesterol treatment goals. Proc Singapore Healthc. 2017;26(3):158-165. doi:10.1177/2010105817694906
  12. Perhimpunan Dokter Spesialis Kardiovaskular Indonesia. Pedoman tatalaksana dislipidemia di Indonesia. J Kardiol Indones. 2013;1:1-60.
  13. Qi L, Ding X, Tang W, Li Q, Mao D, Wang Y. Prevalence and risk factors associated with dyslipidemia in Chongqing, China. Int J Environ Res Public Health. 2015;12(10):13455-13465. doi:10.3390/ijerph121013455
  14. Jellinger PS, Handelsman Y, Rosenblit PD, et al. American Association of Clinical Endocrinologists and American College of Endocrinology Guidelines for Management of Dyslipidemia and Prevention of Cardiovascular Disease. Endocr Pract. 2017;23(April):1-87. doi:10.4158/EP171764.APPGL
  15. Wiratmoko W, Anggunan. Hubungan Antara Kolesterol Total , Trigliserida Dan Status Vaskuler ( Abi ). J Med Malahayati. 2014;1(3):101-106.
  16. Malhotra, N., Keshan, M., dan Agarwal A. DemographIc Assessment and EValuation of DEgree of Lipid Control in High Risk Indian DySlipidemia PatiEnts (DIVERSE Study). J Assoc Physicians India. 2016;64:38-46.
  17. Zhu Y, Hu H, Yang J, et al. The efficacy and safety of statin in combination with ezetimibe compared with double-dose statin in patients with high cardiovascular risk: A meta-analysis. Bosn J Basic Med Sci. 2020;20(2):169-182. doi:10.17305/bjbms.2019.4437
  18. Riddle M et all. American Diabetes Association strandards of medical care in diabetes 2021. J diabetes care. 2021;44(1):133. https://care.diabetesjournals.org/content/diacare/suppl/2020/12/09/44.Supplement_1.DC1/DC_44_S1_final_copyright_stamped.pdf
  19. Bolli P. Treatment of dyslipidemia: The problem of reaching the goal. Elsevier. 2014;236(1):142-143. doi:10.1016/j.atherosclerosis.2014.06.003
  20. Chen YH, Du L, Geng XY, et al. Effects of sulfonylureas on lipids in type 2 diabetes mellitus: A meta-analysis of randomized controlled trials. J Evid Based Med. 2015;8(3):134-148. doi:10.1111/jebm.12157
  21. Soelistijo. S. et al. Pedoman Pengelolaan Dan Pencegahan Diabetes Melitus Tipe 2 Dewasa Di Indonesia 2019. PB. PERKENI; 2019.
  22. Perhimpunan Dokter Spesialis Kardiovaskular Indonesia. Panduan Tata Laksana Dislipidemia 2017. Vol 148. Pehimpunan Dokter Spesialis Kardiovaskular Indonesia; 2017. https://spesialis1.kardio.fk.unair.ac.id/wp-content/uploads/2021/02/PERKI-DYSLIPIDEMIA-2017.pdf



DOI: https://doi.org/10.22146/jmpf.64328

Article Metrics

Abstract views : 3146 | views : 5861

Refbacks

  • There are currently no refbacks.


Copyright (c) 2021 JURNAL MANAJEMEN DAN PELAYANAN FARMASI (Journal of Management and Pharmacy Practice)

Creative Commons License
This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.

©Jurnal Manajemen dan Pelayanan Farmasi
Faculty of Pharmacy
Universitas Gadjah Mada
Creative Commons License
View My Stats